Subacromial Impingement Syndrome Ultrasound-Guided Dextrose Prolotherapy and Corticosteroid Injection
NCT07921238, Not applicable, Completed, Mustafa Kemal University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Subacromial Impingement Syndrome Ultrasound-Guided Dextrose Prolotherapy and Corticosteroid Injection | ClinicalTrials.gov |
| NCT number | NCT07921238 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Mustafa Kemal University | ClinicalTrials.gov |
| Conditions | Sub Acromial Impingement Syndrome | ClinicalTrials.gov |
| Interventions | Prolotherapy group, Corticosteroid group | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Visual Analogue Scale(VAS) | From the enrollment phase to the end of the 12-week treatment period | Pain intensity was assessed using the Visual Analogue Scale (VAS), a 10-cm horizontal line on which patients mark their pain level. Scores range from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate a worse outcome. | ClinicalTrials.gov |
| Primary | Shoulder Pain and Disability Index (SPADI) | From the enrollment phase to the end of the 12-week treatment period | Shoulder pain and function were assessed using the Shoulder Pain and Disability Index (SPADI), a 13-item self-reported questionnaire consisting of a pain subscale (5 items) and a disability subscale (8 items). The total score ranges from 0 (best) to 100 (worst). Higher scores indicate greater pain and disability, i.e., a worse outcome. | ClinicalTrials.gov |
| Secondary | ROM | From the enrollment phase to the end of the 12-week treatment period | Active shoulder range of motion (ROM) was measured in degrees using a universal goniometer for flexion, abduction, internal rotation, and external rotation. Internal and external rotation were measured with the shoulder at 90° abduction. Normal reference ranges are 0-180° for flexion, 0-180° for abduction, 0-90° for internal rotation, and 0-90° for external rotation. Higher values indicate greater mobility, i.e., a better outcome. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)